32
First Semester 2009 Performance
First Semester2009
Performance
Enseval in Brief
3
Milestones
1973 ►
1993 ►
Responding to the government regulation which require separation between role of distribution and role of marketing / manufacturing, PT Enseval was established in October 1973
In 1993, PT Enseval transferred all trading and distribution businesses to PT Arya Gupta Cempaka, a wholly owned subsidiary, which later change its company name to PT Enseval Putera Megatrading
On 1 August 1994, the Company was listed on Jakarta Stock Exchange
4
Milestones
Incorporation of
subsidiary
Millenia Dharma Insani
2003 ►
PT Enseval Putera
Megatrading
conducted its Initial
Public Offering
1988 ►
2007 ►
Incorporation of two
subsidiaries : PT
Enseval Medika
Prima & PT Global
Chemindo
Megatrading
1994 ►
PT Enseval Medika
Prima & PT Global
Chemindo
Megatrading
commenced their
business in October
2008
Incorporation of PT
Renalmed Tiara
Utama which started
operations in the
same year
2008
5
Mission, Vision & Core Values
Mission :
To provide excellent and integrated logistic services in healthcare and related products
Core Values :
•Giving the Best to Customers
•Striving for Excellence
Vision :
To be a regional logistics provider and leading retail service healthcare
leveraging distinct customer service and integrated operations
•Strong Team Work
•Agility
•Integrity
6
Corporate Overview – Enseval Group
PT Enseval Putera
Megatrading Tbk
Renalmed Tiara Utama
97.50 %
Tri Sapta Jaya 99.99%
Millenia Dharma Insani99.00%
Enseval M edika Prima
99.00%
Global Chemindo
Megatrading
99.00%
1%
1%
1%
7
Shares ownership at 30 June 2009
58.2%41.8%
PT Kalbe Farma Tbk Public
33.4%66.6%
Foreign Investor Local Investor
Total number of shares : 2.280.000.000 shares
June
2009
June
2009
8
The largest pharmaceutical distribution network throughout the
Indonesian Archipelago with 41 Branches (EPM), 2 Regional
Distribution Center & 22 Branches under subsidiary company (TSJ)
Branches
9
Over 900 transportation fleetOver 500 motorcycles Over 59,000 pallets size
Infrastructures
The Usage of ORACLE as IT Platform in 40 Branches & usage of PDA System
10
Directly and Indirectly covers more than
1,000,000 outlets
Direct delivery to end customers
Cover most pharmacies & hospital
Cover 80% of consumer & health market
24 hour order fulfillment & 4-5 hour order
fulfillment for prescription pharma
24 hour service for life saving drug
Offers value added services to customers :
- resource management, strategic sourcing & supply
- needs-basis marketing service
Services
11
Employs over 4,000 personnel with over 2,000 personnel are working in sales and distribution
Human Resources
Business Overview
13
Ethical Consumer
Distribution & Logistic
Our service :
Warehousing
Inventory Management
Freight & Transportation
Sales & Support
Order-taking, Billing & Collection
Product Range : Ethical, OTC, Consumer Products, Medical
Device & Raw Material
OTC
14
In 2008, The Company offer marketing service of medical device
through PT Enseval Medika Prima and Hemodialysis Equipment and
supplies through PT Renalmed Tiara Utama.
The company has retained the trust & maintained good relationships
with multi-national principals
Medical Device
Product Range : Consumables, Instruments, Laboratories
& Diagnostics
15
Product Range : Pharmaceutical, Food, Cosmetics & Veterinary
Since 2008, PT Global Chemindo Megatrading operated independently
from its parents and offers trading & marketing of raw
material.
It has extensive network & also collaboration with over 50 foreign
companies
Raw Material
16
Healthcare services through Mitrasana 4 in 1 Clinics
Currently there are 4 clinics open in Cikarang & Bekasi, Jakarta
Healthcare Services
Operational Highlights
18
Ethical
OTC
Consumer
Corporate Overview – Major Principals
19
Medical Device
Raw material
Corporate Overview – Major Principals
Friesland Foods Domo
20
New Principals Update First Semester 2009
Bellco
3M Medical
GE Healthcare
BPC Keylabs & Diagnostics
Boston Scientific
New Principals for Medical Device :
21
Branch Opening & Award
Awarded as The Most Powerful Distribution Performance 2009 for PT Kalbe Farma Tbk Products : Extra Joss, Komix Cough Syrup & Mixagrip on 5th June 2009 From Swa Magazine and QASA Strategic Consulting
Opening of Pejaten Branch on 1st April 2009
Financial Results First Semester 2009
23
First Semester 2009 Summary
Strong Growth Year on Year
Improved Ratios Year on Year
Strong Financial Position with Cash & Cash Equivalents Balance of Rp.402.2 Billion
Net Sales 12.9%
Operating Profit 18.8%
Net Income 14.9%
Gross Profit Margin 0.4%
Operating Profit Margin 0.3%
Net Profit Margin 0.1%
24
4.5
5.3
6.4
7.4
4.0
5.5
17.8%
12.9%
16.1%
15.4%
3.7%
18.9%
2004 2005 2006 2007 2008 YTD June 09
Sales Growth
Sales Growth
The Company recorded Net Sales of IDR 3.987 Billion, achieving 12.9% growth year on year
25
Sales Growth By Division
Medical Devices & Veterinary division recorded significant sales growth year on year.
1,3531,444
785 774
981
1,162
267325
139266
6 16
3,5303,987
Consumer OTC ETH Raw Material Medical Device Veterinary Consolidated
YTD June 08
YTD June 09
Δ 6.7% Δ (1.4%) Δ 22.0%Δ 18.5% Δ 91.6% Δ 168.9% Δ 12.9%
Note : Figures are in IDR Billion
26
Sales Contribution
Consumer
36.2%
OTC
19.4%
ETH
29.2%
Raw Material
8.2%
Veterinary
0.4%Medical
Device, 6.7%
YTD June 2009 Unaudited
Veterinary
0.2%
Consumer
38.3%
OTC
22.2%
ETH
27.8%
Raw Material
7.6%
Medical
Device, 3.9%
YTD June 2009 UnauditedYTD June 2008
Unaudited
27
In First semester 2009, Kalbe’s Group Sales contributes 71% of total sales while the
remaining 29% are from 3rd Party principals
Sales Contribution From 3rd Party & Group
Kalbe
Group 71%
3rd Party
29%
Kalbe
Group
74%
3rd Party
26%
YTD June 2009 Unaudited
YTD June 2008 Unaudited
28
307271
209
244
284
363
5.2%4.9%
4.8%
4.9%5.3%5.4%
2004 2005 2006 2007 2008 YTD June 09
Operating Income Operating Income %
Operating Profit Margin
Operating Profit Margin for First semester 2009 is at Rp. 209.3 Billion with operating margin ratio to net sales is 5.2%
Figures are in IDR Billion
29
178
203
231
266
147
209
4.0% 3.8%3.8%
3.6% 3.6%3.7%
2004 2005 2006 2007 2008 YTD June 09
NPAT NPAT%
Net Profit Margin
Net Profit Margin for first semester 2009 is at Rp. 147.7 Billion with Net profit margin ratio to net sales is 3.7%
Figures are in IDR Billion
30
Earnings Per Share (In IDR)
Net income per share for first semester 2009 is at IDR 65 per share
79
89 92
102
117
65
2004 2005 2006 2007 2008 YTD June 09
31
For Further Information, please contact :
Corporate Secretary
PT Enseval Putera Megatrading Tbk.Enseval Building
Kawasan Industri PulogadungJalan Pulolentut No.10
Jakarta 13920 – IndonesiaPhone : 62-21-46822422 Fax : 62-21-4609039
Website : www.enseval.comEmail : [email protected]
32
This presentation has been prepared for informational purposes only by PT Enseval
Putera Megatrading Tbk. (“Enseval” or the “Company”).
The information contained in this Presentation does not purport to be all-inclusive or to
contain all of the information that may be material to an investor’s decision. It should be
noted that the information contained in this Presentation is subjected to further review,
and that such information may be updated and/or amended from time to time as
circumstances change or more information becomes available. Some of those revisions
or changes may be material.
Each recipient of this Presentation should therefore perform their own independent
analysis of the business, operations, financial condition, creditworthiness, status and
affairs of Enseval. Each recipient should also conduct their own enquiries into the
adequacy, accuracy, and completeness of any information relating to Enseval, as the
information and data contained in this Presentation are not substitutes for the
recipient’s independent evaluation and analysis.
This presentation is not an offering document and will be updated regularly as
necessary.
Important Notice
